Is terbinafine safe for use in lactating mothers, and what are the recommendations for oral versus topical therapy?

Use of Terbinafine in Lactating Mothers

Oral terbinafine is not recommended in nursing mothers, as the drug concentrates in breast milk at 7 times the plasma level, and treatment of onychomycosis can be safely postponed until after breastfeeding is completed. 1

Oral Terbinafine During Lactation

The FDA drug label explicitly states that after oral administration, terbinafine is present in breast milk with a milk-to-plasma ratio of 7:1, meaning the infant would be exposed to significantly higher concentrations than what circulates in the mother's bloodstream 1. Treatment with oral terbinafine is not recommended in nursing mothers 1.

Key Considerations for Oral Therapy:

• High breast milk concentration: The 7:1 milk-to-plasma ratio represents substantial infant exposure
• Non-urgent indication: Onychomycosis is not a life-threatening condition and can be deferred until after lactation
• Long treatment duration: Oral therapy requires 6 weeks for fingernails or 12-16 weeks for toenails 2, representing prolonged infant exposure
• Drug persistence: Terbinafine persists in tissues for 6 months after treatment completion due to its lipophilic nature 2

Topical Terbinafine During Lactation

While the provided evidence does not specifically address topical terbinafine use during lactation, topical formulations result in minimal systemic absorption compared to oral therapy. Topical terbinafine may be considered as a safer alternative for superficial fungal infections during breastfeeding, as systemic exposure would be negligible and breast milk concentrations would be minimal to undetectable.

Clinical Algorithm:

1. If onychomycosis or systemic fungal infection requiring oral therapy: Defer treatment until after breastfeeding is completed, or consider temporary cessation of breastfeeding if treatment cannot be delayed
2. If superficial fungal infection (tinea corporis, tinea pedis): Use topical terbinafine as first-line therapy
3. If oral therapy is absolutely necessary: Discuss risks/benefits with the mother, consider alternative antifungals with better lactation safety profiles, or recommend temporary discontinuation of breastfeeding

Important Caveats:

• The British Association of Dermatologists guidelines 2 do not address lactation safety, focusing instead on efficacy and general safety profiles
• No specific lactation studies exist examining infant outcomes after maternal terbinafine exposure
• The AAP breastfeeding guideline 3 emphasizes that most maternal medications are compatible with breastfeeding, but terbinafine's high milk concentration makes it an exception

The definitive recommendation is to avoid oral terbinafine during lactation based on the FDA drug label warning and the high milk-to-plasma concentration ratio 1.